Transcription of Finance News Network Interview with Noxopharm Limited (ASX:NOX) Managing Director and CEO, Dr Graham Kelly.
Carolyn Herbert: Hello I’m Carolyn Herbert from the Finance News Network and once again I’m joined by Noxopharm Limited (ASX:NOX) CEO and Managing Director, Dr Graham Kelly. Graham, welcome back.
Dr Graham Kelly: Thank you Carolyn.
Carolyn Herbert: Can you start by telling us about your latest discovery and why you’re so excited by it?
Dr Graham Kelly: Certainly we believe it’s very exciting and very important for the company, but it does take some explaining. It’s about the discovery of a form of our major drug Indronoxil that we now call Indronoxil-C. That’s the discovery and that’s why we’re excited.
Carolyn Herbert: So Graham, how is Indronoxil-C different to the Indronoxil that’s currently being used in your NOX66 product?
Dr Graham Kelly: When we deliver Indronoxil to the body in the form of NOX66, what we were trying to achieve was to get the Indronoxil into the body, in exactly the same way that we saw in the test tube, so it would work that well. But what we’ve now discovered in fact is that it comes into the body in a slightly different form. And that different form, which is called Indronoxil-C we now realise is a very smart, a smarter form of Indronoxil. So we’ve actually got a benefit, an increased benefit from the drug and that’s exciting, because this is a new drug. This Indronoxil-C is Indronoxil in a slightly different form, that’s a new drug.
Carolyn Herbert: So what will the purpose of Indronoxil-C be?
Dr Graham Kelly: It’s a smart form of Indronoxil. So when we give a patient NOX66, we’re giving them regular Indronoxil, but by the time it gets into the blood of a patient, it’s converted into this new form. And that’s a form that nobody has seen before, so that’s the exciting part of this NOX66 delivery. So we’re converting it into this very smart form of Indronoxil that we believe is now going to allow us to see in humans, what we see in the test tube.
Carolyn Herbert: You filed a PCT patent for Indronoxil-C. Can you tell us what this is and what it means for Noxopharm’s IP portfolio?
Dr Graham Kelly: PCT stands for Patent Co-operation Treaty and that’s a treaty that 145 countries subscribe to. And when you file a PCT, you are filing in 145 countries. So it’s a way of getting global access to many countries.
Carolyn Herbert: Finally Graham. So how does this discovery of Indronoxil-C potentially benefit shareholders?
Dr Graham Kelly: There’s two ways of answering that question. The first way is that most people believe that the asset of a drug development company is the end drug. That’s all they see. In fact, the assets of a drug development company are its intellectual property. That’s what we’re trading on, but the fact that we own a drug and that’s what we’re going to exploit. But in this particular case, the other answer is that shareholders will see over the coming years, a range of drugs come out. Some of these will be how we use NOX66; others will be how we use this synthetic form of this Indronoxil-C.
Carolyn Herbert: Dr Graham Kelly, thanks for the update.
Dr Graham Kelly: Thank you.